Social cognition: an important but overlooked aspect of cognitive function

/ Insights

Insights Social cognition: an important but overlooked aspect of cognitive function 28 November 2017 Back to resource centre Social cognitive deficits have traditionally been linked with autism spectrum conditions. However, a recent paper from Cambridge Cognition suggests that deficits in social cognition are exhibited across a range of neurological, psychiatric and developmental disorders. Our ability to understand the thoughts and

Social cognition: an important but overlooked aspect of cognitive function Read More »

Wearable devices: the future for near-patient testing?

/ Insights

Insights Back to resource centre 20 November 2017 Wearable devices: the future for near-patient testing? Cognition Kit and Takeda have collaborated to deliver high frequency assessments of mood and cognition in major depressive disorder, using the Apple Watch. Patients with major depressive disorder (MDD) frequently experience cognitive problems such as inattention and memory complaints. These are often under-recognized and can

Wearable devices: the future for near-patient testing? Read More »

MRI research meets Doppler Ultrasound, Cognitive Function and Wellbeing with CANTAB Research Grant

/ Insights

Insights Back to resource centre 8 May 2017 MRI research meets Doppler Ultrasound, Cognitive Function and Wellbeing with CANTAB Research Grant PhD student Claire Burley was one of four winners of our CANTAB Research Grant for 2016. Claire was awarded our UK award for her study titled ‘Multi-modal assessment of brain health across the lifespan and between fitness groups. Magnetic

MRI research meets Doppler Ultrasound, Cognitive Function and Wellbeing with CANTAB Research Grant Read More »

Leveraging Cognitive Measures in Clinical Trials

/ Webinars

Webinars Back to resource centre 11 January 2023 Leveraging Cognitive Measures in Clinical Trials This webinar discussed the assessment of cognitive function throughout the development of drugs for both CNS and non-CNS indications. It included a discussion of methodological considerations for the design of clinical trials and approaches to the analysis and interpretation of cognitive outcome measures for the evaluation

Leveraging Cognitive Measures in Clinical Trials Read More »

Understanding the Clinical Assessment of Abuse Potential during CNS Drug Development

/ Webinars

Webinars Back to resource centre 11 January 2023 Understanding the Clinical Assessment of Abuse Potential during CNS Drug Development This free webinar discussed the why, when and how of collecting, evaluating and interpreting abuse potential data throughout CNS drug development, including a discussion of the design, analysis and interpretation of human abuse potential studies.  Speaker: Kerri A. Schoedel, PhD, Director and

Understanding the Clinical Assessment of Abuse Potential during CNS Drug Development Read More »

Assessing Cognitive Safety of Drugs in Clinical Development

/ Webinars

Webinars Back to resource centre 11 January 2023 Assessing Cognitive Safety of Drugs in Clinical Development In this webinar, Dr Kenton Zavitz, Director of Clinical Affairs discusses assessing cognitive safety of drugs in clinical development.  Speakers: Kenton H. Zavitz, PhD, Director of Clinical Affairs Pradeep Nathan, PhD, Vice President Neuroscience Scientific Strategy Lead and Head, Neuroscience Center of Innovation, inVentiv Health Key Discussion Points: What

Assessing Cognitive Safety of Drugs in Clinical Development Read More »

CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab

/ News

News Back to resource centre 16 March 2017 CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab Cambridge Cognition today reports its involvement in Amgen’s EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.Cambridge Cognition reports its involvement in Amgen’s EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on

CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab Read More »

CANTAB Mobile awarded FDA clearance

/ News

News Back to resource centre 25 January 2017 CANTAB Mobile awarded FDA clearance Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration (‘FDA’) to market its CANTAB Mobile product as a medical device in the U.S.Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration (‘FDA’) to market CANTAB Mobile as a medical device in the U.S.CANTAB

CANTAB Mobile awarded FDA clearance Read More »

Autifony Therapeutics Continues Evaluation of AUT00206 for the Treatment of Schizophrenia

/ News

News Back to resource centre 12 January 2017 Autifony Therapeutics Continues Evaluation of AUT00206 for the Treatment of Schizophrenia Autifony Therapeutics recently presented a poster at the American College of Neuropsychopharmacology following their first human Phase I study in healthy male volunteers to investigate a novel treatment for the positive, negative and cognitive symptoms of schizophrenia.Autifony Therapeutics recently presented a

Autifony Therapeutics Continues Evaluation of AUT00206 for the Treatment of Schizophrenia Read More »

Cognitive Assessment Throughout Development

/ Insights

Insights Back to resource centre 30 November 2016 Cognitive Assessment Throughout Development Psychologists often use specific tests which have been specially designed to work well with children. What factors should be considered when choosing a good cognitive test for assessing young people using CANTAB? Although most people might immediately think of a need for cognitive tests in diseases associated with

Cognitive Assessment Throughout Development Read More »

Cambridge Cognition
Scroll to Top